316 related articles for article (PubMed ID: 33553485)
1. Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning.
Nonnenmacher M; Wang W; Child MA; Ren XQ; Huang C; Ren AZ; Tocci J; Chen Q; Bittner K; Tyson K; Pande N; Chung CH; Paul SM; Hou J
Mol Ther Methods Clin Dev; 2021 Mar; 20():366-378. PubMed ID: 33553485
[TBL] [Abstract][Full Text] [Related]
2. Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in mice.
Drouyer M; Merjane J; Nazareth D; Knight M; Scott S; Liao SHY; Ginn SL; Zhu E; Alexander IE; Lisowski L
Mol Ther; 2024 Mar; 32(3):818-836. PubMed ID: 38297833
[TBL] [Abstract][Full Text] [Related]
3. Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.
Castle MJ; Turunen HT; Vandenberghe LH; Wolfe JH
Methods Mol Biol; 2016; 1382():133-49. PubMed ID: 26611584
[TBL] [Abstract][Full Text] [Related]
4. Selection of an Efficient AAV Vector for Robust CNS Transgene Expression.
Hanlon KS; Meltzer JC; Buzhdygan T; Cheng MJ; Sena-Esteves M; Bennett RE; Sullivan TP; Razmpour R; Gong Y; Ng C; Nammour J; Maiz D; Dujardin S; Ramirez SH; Hudry E; Maguire CA
Mol Ther Methods Clin Dev; 2019 Dec; 15():320-332. PubMed ID: 31788496
[TBL] [Abstract][Full Text] [Related]
5. Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model.
Song R; Pekrun K; Khan TA; Zhang F; Paşca SP; Kay MA
Mol Ther Methods Clin Dev; 2022 Dec; 27():73-88. PubMed ID: 36186955
[TBL] [Abstract][Full Text] [Related]
6. Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain.
Zhang X; Chai Z; Lee Dobbins A; Itano MS; Askew C; Miao Z; Niu H; Samulski RJ; Li C
Biomaterials; 2022 Feb; 281():121340. PubMed ID: 34998171
[TBL] [Abstract][Full Text] [Related]
7. A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates.
Wang D; Li S; Gessler DJ; Xie J; Zhong L; Li J; Tran K; Van Vliet K; Ren L; Su Q; He R; Goetzmann JE; Flotte TR; Agbandje-McKenna M; Gao G
Mol Ther Methods Clin Dev; 2018 Jun; 9():234-246. PubMed ID: 29766031
[TBL] [Abstract][Full Text] [Related]
8. Crossing the blood-brain barrier with AAV vectors.
Liu D; Zhu M; Zhang Y; Diao Y
Metab Brain Dis; 2021 Jan; 36(1):45-52. PubMed ID: 33201426
[TBL] [Abstract][Full Text] [Related]
9. Cell-penetrating peptides enhance the transduction of adeno-associated virus serotype 9 in the central nervous system.
Meng Y; Sun D; Qin Y; Dong X; Luo G; Liu Y
Mol Ther Methods Clin Dev; 2021 Jun; 21():28-41. PubMed ID: 33768127
[TBL] [Abstract][Full Text] [Related]
10. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates.
Yao Y; Wang J; Liu Y; Qu Y; Wang K; Zhang Y; Chang Y; Yang Z; Wan J; Liu J; Nakashima H; Lawler SE; Chiocca EA; Cho CF; Bei F
Nat Biomed Eng; 2022 Nov; 6(11):1257-1271. PubMed ID: 36217021
[TBL] [Abstract][Full Text] [Related]
11. AAV Engineering for Improving Tropism to the Central Nervous System.
Ghauri MS; Ou L
Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829465
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS.
Stanton AC; Lagerborg KA; Tellez L; Krunnfusz A; King EM; Ye S; Solomon IH; Tabebordbar M; Sabeti PC
Med; 2023 Jan; 4(1):31-50.e8. PubMed ID: 36417917
[TBL] [Abstract][Full Text] [Related]
13. CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain.
Mathiesen SN; Lock JL; Schoderboeck L; Abraham WC; Hughes SM
Mol Ther Methods Clin Dev; 2020 Dec; 19():447-458. PubMed ID: 33294493
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated viral vectors and their redirection to cell-type specific receptors.
Michelfelder S; Trepel M
Adv Genet; 2009; 67():29-60. PubMed ID: 19914449
[TBL] [Abstract][Full Text] [Related]
15. In vivo selection in non-human primates identifies AAV capsids for on-target CSF delivery to spinal cord.
Hanlon KS; Cheng M; Ferrer RM; Ryu JR; Lee B; De La Cruz D; Patel N; Espinoza P; Santoscoy MC; Gong Y; Ng C; Nguyen DM; Nammour J; Clark SW; Heine VM; Sun W; Kozarsky K; Maguire CA
Mol Ther; 2024 Jun; ():. PubMed ID: 38845196
[TBL] [Abstract][Full Text] [Related]
16. A NEW RECOMBINANT ADENO-ASSOCIATED VIRUS (AAV)-BASED RANDOM PEPTIDE DISPLAY LIBRARY SYSTEM: INFECTION-DEFECTIVE AAV1.9-3 AS A NOVEL DETARGETED PLATFORM FOR VECTOR EVOLUTION.
Adachi K; Nakai H
Gene Ther Regul; 2010 Oct; 5(1):31-55. PubMed ID: 21603583
[TBL] [Abstract][Full Text] [Related]
17. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy.
Yang L; Li J; Xiao X
Methods Mol Biol; 2011; 709():127-39. PubMed ID: 21194025
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.
Matsuzaki Y; Konno A; Mochizuki R; Shinohara Y; Nitta K; Okada Y; Hirai H
Neurosci Lett; 2018 Feb; 665():182-188. PubMed ID: 29175632
[TBL] [Abstract][Full Text] [Related]
19. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors.
Varadi K; Michelfelder S; Korff T; Hecker M; Trepel M; Katus HA; Kleinschmidt JA; Müller OJ
Gene Ther; 2012 Aug; 19(8):800-9. PubMed ID: 21956692
[TBL] [Abstract][Full Text] [Related]
20. Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells.
Merkel SF; Andrews AM; Lutton EM; Mu D; Hudry E; Hyman BT; Maguire CA; Ramirez SH
J Neurochem; 2017 Jan; 140(2):216-230. PubMed ID: 27718541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
